Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667916 | 1.00 | MAPK1 (0.37) | MAPK1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL21667917 | 1.00 | MAPK1 (0.37) | MAPK1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL21941052 | 0.85 | SLC6A1 (0.33) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL20028807 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL19476575 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL20027939 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL9540274 | 0.81 | SLC6A1 (0.33) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL20934678 | 0.79 | SLC6A1 (0.42) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL21941843 | 0.79 | SMN1; SMN2 (0.44) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL21743169 | 0.79 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | MAPK1 3668/4885SLC6A1 2644/4885GABRA5 4338/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | MAPK1 4061/4885SLC6A1 803/4885GABRA5 2865/4885 |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | MAPK1 3466/4885SLC6A1 778/4885GABRA5 3593/4885 |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | MAPK1 4125/4885SLC6A1 994/4885GABRA5 2661/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | MAPK1 3668/4885SLC6A1 2644/4885GABRA5 4338/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | MAPK1 4607/4885SLC6A1 1202/4885GABRA5 2597/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | MAPK1 3668/4885SLC6A1 2644/4885GABRA5 4338/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | MAPK1 4115/4885SLC6A1 2885/4885GABRA5 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.